EGFR and non-small cell lung carcinoma: In non-small cell lung cancers sensitive to EGFR tyrosine kinase inhibition is lost usually due to ‘gatekeeper’ mutation however surprisingly acquisition of BRAF gatekeeper ‘mutations’ do not account for secondary drug resistance in melanoma that acquire resistance to BRAF inhibitors.